

5
U.S.
5/22/02

JC14 Rec'd PCT/PTO 22 MAY 2002 1653412

PCT

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FORM PTO-1390 (Modified) EFS-2000		ATTORNEY DOCKET NUMBER MCP-0054
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 10/018,314
INTERNATIONAL APPLICATION NO. PCT/US00/11902	INTERNATIONAL FILING DATE 2 May 2000	PRIORITY DATE CLAIMED 4 May 1999
TITLE OF INVENTION Structure-Based Design of Compounds that Inhibit Detrimental Cytotoxic T Lymphocyte Responses		
APPLICANT(S) FOR DO/EO/US JAMESON, Bradford A. et al.		
<p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:</p> <p>1. <input type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input checked="" type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.</p> <p>4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</p> <p>5. <input type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2))</p> <p>a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</p> <p>b. <input type="checkbox"/> has been communicated by the International Bureau.</p> <p>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p>a. <input type="checkbox"/> is attached hereto.</p> <p>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</p> <p>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))</p> <p>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</p> <p>b. <input type="checkbox"/> have been communicated by the International Bureau.</p> <p>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p>d. <input type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).</p> <p>11. <input type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409).</p> <p>12. <input type="checkbox"/> A copy of the International Search Report (PCT/ISA/210).</p> <p>Items 13 to 20 below concern document(s) or information included:</p> <p>13. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>14. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>15. <input type="checkbox"/> A FIRST preliminary amendment.</p> <p>16. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment</p> <p>17. <input type="checkbox"/> A substitute specification.</p> <p>18. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>19. <input type="checkbox"/> A computer-readable form of the sequence listing in a</p> <p>20. <input type="checkbox"/> A second copy of the published international applicati</p> <p>21. <input type="checkbox"/> A second copy of the English language translation of t</p> <p>22. <input type="checkbox"/> Certificate of Mailing by Express Mail</p> <p>23. <input checked="" type="checkbox"/> Other items or information:</p> <p>1) Notification of Missing Requirements; 2) Substitute copy of computer readable form of Sequence Listing; and 3) Statement to Support Filing and Submission in Accordance with 37 CFR 1.821-1.825</p>		
<p>"Express Mail" Label No. EV104364851US Date of Deposit May 22, 2002</p> <p>I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the U.S. Patent and Trademark Office, Box Missing Parts, Post Office Box 2327, Arlington, VA 22202</p> <p>By <u>Deborah Ehret</u> Typed Name: Deborah Ehret</p>		

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.492)	INTERNATIONAL APPLICATION NO.	ATTORNEY'S DOCKET NUMBER
10/018,314	PCT/US00/11902	MCP-0054

24. The following fees are submitted:.

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO	\$1040.00
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO	\$890.00
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO	\$740.00
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)	\$710.00
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)	\$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$0.00

Surcharge of **\$130.00** for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)).

20 30

\$130.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	- 20 =	0	x \$18.00	\$0.00
Independent claims	- 3 =	0	x \$84.00	\$0.00

Multiple Dependent Claims (check if applicable).

TOTAL OF ABOVE CALCULATIONS = **\$130.00**

Applicant claims small entity status. See 37 CFR 1.27). The fees indicated above are reduced by 1/2.

\$65.00

SUBTOTAL = **\$65.00**

Processing fee of **\$130.00** for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)).

20 30

\$0.00

TOTAL NATIONAL FEE = **\$65.00**

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).

\$40.00

TOTAL FEES ENCLOSED = **\$105.00**

Amount to be: refunded	\$
charged	\$


- A check in the amount of _____ to cover the above fees is enclosed.
- Please charge my Deposit Account No. 50-1619 in the amount of \$105.00 to cover the above fees. A duplicate copy of this sheet is enclosed.
- The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-1619 A duplicate copy of this sheet is enclosed.
- Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Jane Massey Licata, Reg. No. 32,257
Kathleen A. Tyrrell, Reg. No. 38,350
Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

Telephone: (856) 810-1515
Facsimile: (856) 810-1454


SIGNATURE

Kathleen A. Tyrrell

NAME

38,350

REGISTRATION NUMBER

May 22, 2002

DATE

PROCT Rec'd 22 MAY 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: MCP-0054

Inventors: Jameson and Tretiakova

Serial No.: 10/018,314

Filing Date: November 2, 2001

Examiner: Not yet assigned

Group Art Unit: Not yet assigned

Title: Structure-Based Design of Compounds that Inhibit Detrimental Cytotoxic Lymphocyte Response

"Express Mail" Label No. EV104364851US
Date of Deposit - May 22, 2002

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327 Arlington, VA 22202

By Kathleen A. Tyrell
Typed Name: Kathleen A. Tyrell

Assistant Commissioner for Patents
BOX Sequence
United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 CFR §§ 1.821 THROUGH 1.825

() I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively are the same.

() I hereby state that the submission filed in accordance with 37 CFR §1.821(g) does not include new matter.


() I hereby state that the submission filed in accordance with **37 CFR §1.821(h)** does not include new matter or go beyond the disclosure in the international application as filed.

() I hereby state that the amendments, made in accordance with **37 CFR §1.825(a)**, included in the substitute sheet(s) of the Sequence Listing were made to conoform to the current Sequence Listing Rules. I hereby state that the substitute sheet(s) of the Sequence Listing does not include new matter.

() I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 CFR §1.825(b)**, is the same as the amended Sequence Listing submitted herewith.

(XX) I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 CFR §1.825(d)**, contains identical data to that originally filed.

Respectfully submitted,



Kathleen A. Tyrrell
Registration No. 38,350

Date: **May 22, 2002**

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515